Gives replace on Aikido Pharma share repurchase program


New York, September 30, 2022 /PRNewswire/ — AIkido Pharma Inc. (NASDAQ:AIKI) (“AIkido” or the “Firm”) at the moment supplied an replace on $3 million Share Repurchase Program (“Share Repurchase Program”) approved by the Firm’s Board of Administrators 21 January 2022,

As a part of the share repurchase programme, the corporate has repurchased 303,886 widespread shares in the course of the interval. 21 January 2022 as much as and together with September 29, 2022, The worth per share restrict for the repurchased shares was $5.34 To $6.97,

Further shares might occasionally be exchanged in open market transactions, or by different means pursuant to Rule 10b5-1 of the Securities Alternate Act 1934 (“The Alternate Act”), and Guidelines 10b -18 of the Alternate Act. Timing, variety of shares repurchased and costs paid for inventory beneath this program depend upon regular enterprise and market circumstances in addition to company and regulatory limits, together with blackout interval restrictions.

About Aikido Pharma Inc.

AIkido Pharma Inc. was based in 1967 and is a biotechnology firm with a various portfolio of small-molecule anticancer and antiviral therapeutics. The corporate’s platform incorporates patented know-how from main universities and researchers, and we’re at present within the technique of growing an modern therapeutic drug platform by means of sturdy partnerships with world-renowned tutorial establishments, together with College of Texas at Austin And College of Maryland in Baltimore, Our various pipeline of therapeutics contains therapies for pancreatic most cancers, prostate most cancers. We’re regularly in search of to develop our pipeline to deal with unmet medical wants in oncology. The corporate can be growing a broad-spectrum antiviral platform that may doubtlessly inhibit the replication of a number of viruses, together with Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

forward-looking statements

Sure statements on this press launch represent “forward-looking statements” throughout the that means of federal securities legal guidelines. phrases corresponding to “may,” “may,” “will,” “ought to,” “consider,” “anticipate,” “estimate,” “estimate,” “proceed,” “predict,” “forecast, “Undertaking,” “plan,” “intent” or related expressions, or statements about intention, perception, or present expectations, are forward-looking statements. Whereas the Firm believes these forward-looking statements are affordable, undue reliance shouldn’t be positioned on any forward-looking statements which might be based mostly on info obtainable to us on the date of this launch. These forward-looking statements are based mostly on present estimates and assumptions and are topic to numerous dangers and uncertainties, together with with out limitation set forth within the firm’s filings with the SEC, together with however not restricted to threat components associated to its enterprise contained herein. Thus, precise outcomes might differ materially. The corporate expressly disclaims any obligation to replace or change the statements for brand spanking new info, future occasions or in any other case, besides as required by regulation.


Investor Relations:

Hayden IR
Brett Maas, Managing Companion
Telephone: (646) 536-7331
E mail:

Aikido Pharma Inc.:

Telephone: 212-745-1373
E mail: Investor

Decision To obtain multimedia, go to the unique content material:

Supply Aikido Pharma Inc.


Supply hyperlink